Azamat Yerlanuly has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Structural Modifications of Hybrid O-Alkylsulfonyl-β-(Benzimidazol-1-yl)propioamidoximes as a Pathway to the Antimicrobial, Antifungal and Antidiabetic Drugs

    by Lyudmila Kayukova, Anna Vologzhanina, Ekaterina Dubasova, Roza Seidakhmetova, Azamat Yerlanuly, Aruzhan Sartoyeva, Aigul Malmakova

    The continuous search for new chemical structures more active and less toxic than those currently in practice is justified on the basis of the use of proven pharmacophoric building blocks (benzimidazole heterocycle, sulfonyl group and amidoxime framework in our case). The aim of the work was to synthesize new O-alkylsulfonyl-β-(benzimidazol-1-yl)propioamidoximes and to test them for in vitro biological activities to identify potentially effective agents. Novel O-alkylsulfonylamidoximes were synthesized in hydrochloride and base forms by the reaction of β-(benzimidazol-1-yl)propioamidoxime with alkylsulfonyl chlorides AlkSO2Cl (Alk = CH3, n-C3H7, i-C3H7, n-C4H9) in a mixture of water:acetone in hydrochloride and base forms. Hydrochlorides and bases of the O-alkylsulfonyl-β-(benzimidazol-1-yl)propioamidoximes were obtained in moderate to high yields. The structures of the synthesized compounds were established by physicochemical and spectral (elemental analysis, FT-IR, NMR and X-ray diffraction) methods. The obtained derivatives were tested for antimicrobial, antifungal and antidiabetic activity. Biological screening found effective samples of amidoximes with antimicrobial and antifungal activities that were near or exceeded the activity of the reference drugs gentamicin and nystatin; in addition, two samples with antidiabetic activity higher than acarbose were found. The results of the present study open new possibilities for the novel β-aminopropioamidoxime class as active antimicrobial and antifungal agents, as well as antidiabetic ones.

  • Open Access

    Structural Modifications of Hybrid O-Alkylsulfonyl-β-(benzimidazol-1-yl)propioamidoximes as a Pathway to the Antimicrobial, Antifungal and Antidiabetic Drugs

    by Lyudmila Kayukova, Anna Vologzhanina, Ekaterina Dubasova, Roza Seidakhmetova, Azamat Yerlanuly, Aruzhan Sartoyeva, Aigul Malmakova

    The continuous search for new chemical structures more active, less toxic than those currently in practice is justified on the basis of the use of proven pharmacophoric building blocks (benzimidazole heterocycle, sulfonyl group and amidoxime framework in our case). The aim of the work was to synthesize new O-alkylsulfonyl- b -(benzimidazol-1-yl)propioamidoximes and to test them for in vitro biological activities to identify potential effective agents. Novel O-alkylsulfonylamidoximes were synthesized by the reaction of b -(benzimidazol-1-yl)propioamidoxime with alkylsulfonyl chlorides AlkSO2Cl (Alk = CH3, n-C3H7, i-C3H7, n-С4H9) in a mixture of water: acetone in hydrochloride and base forms. Obtained derivatives were tested for antimicrobial, antifungal and antidiabetic activity. Hydrochlorides and bases of the O-alkylsulfonyl- b -(benzimidazol-1-yl)propioamidoximes were obtained in moderate to high yields. The structures of the synthesized compounds were established by physicochemical and spectral (FT-IR, NMR and X-ray diffraction) methods. Biological screening found effective samples of amidoximes with antimicrobial and antifungal activities which were near or exceeded the activity of the reference drugs gentamicin and nystatin; in addition, two samples with antidiabetic activity higher than acarbose were found. Results of the present study open new possibilities for the novel b -aminopropioamidoxime class as active antimicrobial and antifungal agents, as well as antidiabetics ones.

  • Open Access

    A Systematic Review of Advanced Drug Delivery Systems: Engineering Strategies, Barrier Penetration, and Clinical Progress (2016–April 2025)

    by Assem B. Uzakova, Elmira M. Yergaliyeva, Azamat Yerlanuly, Zhazira S. Mukatayeva

    Background/Objectives: Advanced drug delivery systems (DDSs) are essential for targeted delivery, controlled release, and reduced systemic toxicity, but their clinical adoption is limited by biological barriers, manufacturing complexities, and cost. The aim of this systematic review is to critically evaluate the quantitative relationships between platform design, overcoming biological barriers, and clinical translation outcomes for DDS developed between 2016 and 2025. Methods: A comprehensive literature search was conducted in PubMed/MEDLINE, Scopus, and Web of Science (January 2016–April 2025) in accordance with the PRISMA 2020 guidelines. Included studies focused on experimental or clinical data for nanocarrier platforms (liposomes, lipid nanoparticles, polymer systems, biomimetic carriers, extracellular vesicles). Data on platform characteristics, interactions with barriers, pharmacokinetics, manufacturing, and clinical outcomes were extracted and synthesized in narrative form due to the significant methodological heterogeneity. Results: An analysis of 77 included studies confirms that successful clinical translation depends on matching the physicochemical properties of the carrier (size, surface chemistry, material) to specific biological barriers. Liposomes and lipid nanoparticles (LNPs) remain the most clinically validated platforms, exploiting the EPR effect and liver tropism, respectively. Key engineering solutions include stealth coatings, ligand-mediated targeting, and stimulus-responsive materials to overcome barriers such as mononuclear phagocyte system clearance, the blood–brain barrier, and mucosal barriers. Microfluidic and continuous manufacturing processes enable reproducibility, but scalability, cost, and immunogenicity (e.g., anti-PEG responses) remain key translational challenges. Engineered extracellular vesicles, biomimetic carriers, and 3D/4D-printed systems combined with AI-driven design demonstrate the potential for personalized, adaptive delivery. Conclusions: Cutting-edge DDSs have validated their clinical value, but realizing their full potential requires a holistic, patient-centered design approach integrating barrier-specific engineering, scalable manufacturing, and rigorous safety assessment from the earliest stages of development. Further progress will depend on standardizing methods for new platforms (e.g., extracellular vesicles), implementing digital and AI tools, and ensuring translational feasibility as a fundamental principle.


  • Open Access

    β-Aminopropioamidoximes derivatives as potential antitubercular agents against anthropozoonotic infections caused by Mycobacterium tuberculosis and Mycobacterium bovis

    by Lyudmila Kayukova, Venera Bismilda, Kairat Turgenbayev, Asem Uzakova, Gulnur Baitursynova, Umirzak Jussipbekov, Meruyert Mukanova, Lyailya Chingissova, Gulnur Dyussembayeva, Assiya Borsynbayeva, et al.

    Background and Aim: Tuberculosis (TB) remains a significant global health challenge, with increasing incidences of drug-sensitive (DS) and multidrug-resistant (MDR) TB. In addition, Mycobacterium bovis-induced zoonotic TB (zTB) presents treatment difficulties due to its resistance to pyrazinamide and the prolonged treatment duration required. This study aims to evaluate the antitubercular potential of β-aminopropioamidoxime derivatives against DS and MDR Mycobacterium tuberculosis and M. bovis strains, and utilizing the SwissADME prognostic tool to predict the drug- and lead-likeness of the described compounds. Materials and Methods: Six β-aminopropioamidoxime derivatives were synthesized through O-aroylation of amidoxime followed by dehydration to form 1,2,4-oxadiazoles. The compounds were tested in vitro against DS, MDR M. tuberculosis, and M. bovis using Sotton’s liquid medium and subcultured on dense Lowenstein-Jensen medium. SwissADME was used to predict drug-likeness and pharmacokinetic properties. Results: The derivatives exhibited significant antitubercular activity, with in vitro efficacy 5–100 times greater than rifampicin. 1,2,4-oxadiazoles with para-bromo and meta-chloro substituents demonstrated the highest activity against DS and MDR M. tuberculosis, while O-para-toluoyl-β-(morpholin-1-yl)propioamidoxime salts (hydrochloride, oxalate and citrate) were 10 times more active against M. bovis. SwissADME analysis confirmed favorable pharmacokinetic properties, including high gastrointestinal absorption and drug-likeness, with lead-likeness identified in four compounds. Conclusion: The study presents β-aminopropioamidoxime derivatives as promising candidates for antitubercular therapy against both human and zTB. Their enhanced activity, oral bioavailability, and potential integration into new treatment regimens underscore their therapeutic relevance. Further in vivo studies are recommended to validate their efficacy and safety for clinical applications. Keywords: antitubercular agents, Mycobacterium bovis, Mycobacterium tuberculosis, SwissADME, tuberculosis, β-aminopropioamidoximes.